EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) today reported promising data from the third stage of its phase Ib/IIa trial assessing iontophoretic EGP-437 for the treatment of ocular inflammation and pain in post-surgical cataract patients. Consistent with the first two stages of the trial, the procedure was very well tolerated in all subjects. Stage three of this multi-center, open-label clinical trial enrolled 30 subjects who have undergone cataract surgery with implantation of a posterior chamber intraocular lens (“IOL”). Patients were divided into three groups receiving iontophoretic doses of EGP-437 at either 4.5 mA-min or 14.0 mA-min, or a placebo at 14.0 mA-min. A positive response, determined by a reduction in Anterior Chamber Cell (“ACC”) count, was observed in patients in both of the EGP-437 treatment arms. Those who were administered 4.5 mA-min dosing realized the greatest benefit, with 80% of patients at day 28 achieving an ACC count of zero in comparison to only 10% of the placebo group. Patients receiving EGP-437 at both dosing levels experienced reduced pain at all time points. The company plans to initiate a randomized, double-masked, placebo-controlled study in the first half of 2017. “The results of this study demonstrate the promise of EGP-437, and we look forward to further demonstrating its ability to improve care for this significant patient population in the upcoming randomized controlled trial,” Stephen From, CEO of EyeGate, stated in the news release.
To view the full press release, visit: http://nnw.fm/Sz2Tg
About EyeGate
EyeGate is a clinical-stage specialty pharmaceutical company that is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. EGP-437, the Company’s first product in clinical trials, incorporates a reformulated topically active corticosteroid, Dexamethasone Phosphate that is delivered into the ocular tissues through EyeGate’s proprietary innovative drug delivery system, the EyeGate® II Delivery System. In addition, EyeGate is developing, through its wholly-owned Jade subsidiary, products using cross-linked thiolated carboxymethyl hyaluronic acid (“CMHA-S”), a modified form of the natural polymer hyaluronic acid (“HA”), which possesses unique physical and chemical properties such as viscoelasticity and water retention. The ability of CMHA-S to adhere longer to the ocular surface, resist degradation and protect the ocular surface make it well-suited for treating various ocular surface injuries. For more information, please visit www.EyeGatePharma.com.
About NetworkNewsBreak
NetworkNewsBreak (NNB) provides a rapid summary of corporate news that caught the attention of NetworkNewsWire (NNW). NNB keeps you up-to-date on active US Public Companies complementary to NNW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW is uniquely positioned to best serve private and public companies who need to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information, visit https://www.networknewswire.com.
Please see full disclaimers on the NetworkNewsWire website: http://nnw.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.net
